

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

CD3

RRID:AB_2890105

Type: Antibody

Proper Citation

ZSGB-Bio Cat# ZM-0417, RRID:AB_2890105

Antibody Information

URL: http://antibodyregistry.org/AB_2890105

Proper Citation: ZSGB-Bio Cat# ZM-0417, RRID:AB_2890105

Target Antigen: CD3

Clonality: monoclonal

Comments: Applications: IHC

Antibody Name: CD3

Description: This monoclonal targets CD3

Clone ID: LN10

Antibody ID: AB_2890105

Vendor: ZSGB-Bio

Catalog Number: ZM-0417

Record Creation Time: 20250820T011523+0000

Record Last Update: 20250820T102653+0000

Ratings and Alerts

No rating or validation information has been found for CD3.

No alerts have been found for CD3.

Data and Source Information

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. *Immunity*, 58(6), 1572.

Tang J, et al. (2025) Protein-based classification reveals an immune-hot subtype in IDH mutant astrocytoma with worse prognosis. *Cancer cell*.

Wang H, et al. (2024) Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. *Med (New York, N.Y.)*, 5(10), 1237.

Lin J, et al. (2023) Fas/FasL and Complement Activation are Associated with Chronic Active Epstein-Barr Virus Hepatitis. *Journal of clinical and translational hepatology*, 11(3), 540.

Wu RQ, et al. (2023) Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. *Immunity*, 56(1), 180.

Duan J, et al. (2023) Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma. *Cell reports. Medicine*, 4(12), 101302.